ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

CDXS Codexis Inc

4.83
-0.16 (-3.21%)
09 Jan 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Codexis Inc NASDAQ:CDXS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.16 -3.21% 4.83 4.13 5.50 4.9403 4.59 4.88 704,342 00:39:33

Codexis to Participate in TD Cowen 2nd Annual Sustainability Week

20/05/2024 9:05pm

GlobeNewswire Inc.


Codexis (NASDAQ:CDXS)
Historical Stock Chart


From Jan 2024 to Jan 2025

Click Here for more Codexis Charts.

Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a panel discussion titled, “Sustainable API Manufacturing” at the TD Cowen 2nd Annual Sustainability Week, being held virtually May 21-23, 2024. During the presentation, Management will highlight the potential benefits of an enzymatic route of synthesis in the manufacture of small molecule and siRNA therapeutics.

The panel will take place on Wednesday, May 22, 2024, at 4:25 pm ET. A live webcast of the event will be available here and in the Investor Relations section of the Company’s website, https://www.codexis.com/investors. A replay will be archived for 90 days following the event.

About Codexis

Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.

For More Information

Investor ContactCarrie McKim(336) 608-9706ir@codexis.com

Media ContactLauren Musto(650) 421-8205media@codexis.com

1 Year Codexis Chart

1 Year Codexis Chart

1 Month Codexis Chart

1 Month Codexis Chart

Your Recent History

Delayed Upgrade Clock